The Effects of ProAlgaZyme Novel Algae Infusion Alone or in Combination With HAART on Markers of Immune Status, Dyslipidemia, Inflammation and Oxidative Stress in HIV or HIV/HBV Patients
Sponsor study identifier
Secondary identifiers
interventional
59
1 country
1
Study Start
May 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 2006
Actual (reported)The purpose of this study is to determine the safety and effects in HIV patients of supplementation (4-20 fl. oz. daily) with ProAlgaZyme, a novel fermentation product of a freshwater algae ecosystem, on markers of immune status, dyslipidemia, inflammation and oxidative stress alone or in combination with HAART (highly-active antiretroviral therapy).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2006
Date type not reportedThis date has not been verified as actual or estimated.
September 2006
Actual (reported)June 26, 2007
Actual (reported)June 28, 2007
Actual (reported)CD4+ T-lymphocytes
12 weeks
HIV Viral Load
12 weeks
hsCRP (C-reactive protein)
12 weeks
Total cholesterol
12 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I
Yaoundé, Cameroon
Julius Oben, Ph.D.
Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon
59 participants (actual enrollment reported by the registry).
First Submitted
June 26, 2007
First Posted
June 28, 2007
Study Start
May 2006
Date type not reportedThis date has not been verified as actual or estimated.
Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels
Liver enzymes (ALT, ALP, GGT)
12 weeks
MDA (malonaldehyde) and thiol proteins
12 weeks
RBC and WBC counts
12 weeks
Contact the study team to confirm eligibility.
Study Completion
September 2006
Actual (reported)Last Updated
June 28, 2007
Record last verified: 2007-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: